Quantum Genomics S.A. is a biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases, particularly targeting resistant hypertension and heart failure. Founded in 2005 and headquartered in Paris, France, the company addresses unmet medical needs by advancing a new class of drugs based on proprietary mechanisms in cardiovascular pharmacology. Quantum Genomics is noted for its lead drug candidate, firibastat, which is designed to treat patients whose conditions are not adequately managed by existing therapies. The company's research and development efforts are driven by a commitment to scientific innovation and addressing significant gaps in current treatment paradigms. With a strong emphasis on late-stage clinical trials and regulatory strategy, Quantum Genomics collaborates with global partners to bring novel solutions to market. Its work plays a meaningful role in the healthcare and biotechnology sectors, aiming to improve outcomes for patients with life-threatening cardiovascular conditions.